Bile Acid Network and Vascular Calcification-Associated Diseases: Unraveling the Intricate Connections and Therapeutic Potential

References

• Cai J, Rimal B, Jiang C, et al. Bile acid metabolism and signaling, the microbiota, and metabolic disease. Pharmacol Ther. 2022;237:108238. doi:10.1016/j.pharmthera.2022.108238
   PubMed Web of Science ®Google Scholar
• Kalhan SC, Guo L, Edmison J, et al. Plasma Metabolomic Profile in Non-Alcoholic Fatty Liver Disease. Metabolism. 2011;60(3):404–413. doi:10.1016/j.metabol.2010.03.006
   PubMed Web of Science ®Google Scholar
• Grant SM, DeMorrow S. Bile Acid Signaling in Neurodegenerative and Neurological Disorders. Int J Mol Sci. 2020;21(17):5982. doi:10.3390/ijms21175982
   PubMed Web of Science ®Google Scholar
• Iijima K. [Bone and calcium update; diagnosis and therapy of bone metabolism disease update. Regulatory Mechanism of Mammalian Sirtuin SIRT1 in Vascular calcification: impact of vascular smooth muscle cell senescence]. Clin Calcium. 2011;21(12):53–60.
   PubMedGoogle Scholar
• Pan W, Jie W, Huang H. Vascular calcification: molecular mechanisms and therapeutic interventions. MedComm. 2023;4(1):e200. doi:10.1002/mco2.200
   PubMedGoogle Scholar
• Singh A, Tandon S, Tandon C. An update on vascular calcification and potential therapeutics. Mol Biol Rep. 2021;48(1):887–896. doi:10.1007/s11033-020-06086-y
   PubMed Web of Science ®Google Scholar
• Charach L, Charach G, Karniel E, et al. Peripheral Vascular Disease and Carotid Artery Disease Are Associated with Decreased Bile Acid Excretion. Bioengineering. 2023;10(8):935. doi:10.3390/bioengineering10080935
   PubMedGoogle Scholar
• Shimizu H, Hagio M, Iwaya H, et al. Deoxycholic Acid Is Involved in the Proliferation and Migration of Vascular Smooth Muscle Cells. J Nutr Sci Vitaminol (Tokyo). 2014;60(6):450–454. doi:10.3177/jnsv.60.450
   PubMed Web of Science ®Google Scholar
• Schwabl P, Hambruch E, Seeland BA, et al. The FXR agonist PX20606 ameliorates portal hypertension by targeting vascular remodelling and sinusoidal dysfunction. J Hepatol. 2017;66(4):724–733. doi:10.1016/j.jhep.2016.12.005
   PubMed Web of Science ®Google Scholar
• Kida T, Murata T, Hori M, Ozaki H. Chronic stimulation of farnesoid X receptor impairs nitric oxide sensitivity of vascular smooth muscle. Am J Phys. 2009;296(1):H195–H201. doi:10.1152/ajpheart.00679.2008
   Google Scholar
• Chiang JYL. Bile Acid Metabolism and Signaling. Compr Physiol. 2013;3:1191–1212. doi:10.1002/cphy.c120023
   PubMed Web of Science ®Google Scholar
• Chiang JYL, Ferrell JM. Bile acid receptors FXR and TGR5 signaling in fatty liver diseases and therapy. Am J Physiol Gastrointest Liver Physiol. 2020;318(3):G554–G573. doi:10.1152/ajpgi.00223.2019
   PubMed Web of Science ®Google Scholar
• Shulpekova Y, Shirokova E, Zharkova M, et al. A Recent Ten-Year Perspective: bile Acid Metabolism and Signaling. Molecules. 2022;27(6):1983. doi:10.3390/molecules27061983
   PubMed Web of Science ®Google Scholar
• Chiang JYL, Ferrell JM. Bile Acid Metabolism in Liver Pathobiology. Gene Expr. 2018;18(2):71–87. doi:10.3727/105221618X15156018385515
   PubMedGoogle Scholar
• Wahlström A, Sayin SI, Marschall H-U, Bäckhed F. Intestinal Crosstalk between Bile Acids and Microbiota and Its Impact on Host Metabolism. Cell Metab. 2016;24(1):41–50. doi:10.1016/j.cmet.2016.05.005
   PubMed Web of Science ®Google Scholar
• Fiorucci S, Carino A, Baldoni M, et al. Bile Acid Signaling in Inflammatory Bowel Diseases. Dig Dis Sci. 2021;66(3):674–693. doi:10.1007/s10620-020-06715-3
   PubMed Web of Science ®Google Scholar
• Winston JA, Theriot CM. Diversification of host bile acids by members of the gut microbiota. Gut Microbes. 2019;11(2):158–171. doi:10.1080/19490976.2019.1674124
   PubMed Web of Science ®Google Scholar
• Shin D-J, Wang L. Bile Acid-Activated Receptors: a Review on FXR and Other Nuclear Receptors. In: Fiorucci S, Distrutti E, editors. Bile Acids and Their Receptors. Cham: Springer International Publishing; 2019:51–72.
   Google Scholar
• Asami J, Kimura KT, Fujita-Fujiharu Y, et al. Structure of the bile acid transporter and HBV receptor NTCP. Nature. 2022;606(7916):1021–1026. doi:10.1038/s41586-022-04845-4
   PubMed Web of Science ®Google Scholar
• Chiang JYL, Ferrell JM. Bile Acids as Metabolic Regulators and Nutrient Sensors. Annu Rev Nutr. 2019;39(1):175–200. doi:10.1146/annurev-nutr-082018-124344
   PubMedGoogle Scholar
• Sayin SI, Wahlström A, Felin J, et al. Gut Microbiota Regulates Bile Acid Metabolism by Reducing the Levels of Tauro-beta-muricholic Acid, a Naturally Occurring FXR Antagonist. Cell Metab. 2013;17(2):225–235. doi:10.1016/j.cmet.2013.01.003
   PubMed Web of Science ®Google Scholar
• Wang H, Chen J, Hollister K, et al. Endogenous bile acids are ligands for the nuclear receptor FXR/BAR. Mol Cell. 1999;3(5):543–553. doi:10.1016/s1097-2765(00)80348-2
   PubMed Web of Science ®Google Scholar
• Kong B, Wang L, Chiang JYL, et al. Mechanism of Tissue-specific Farnesoid X Receptor in Suppressing the Expression of Genes in Bile-acid Synthesis in Mice. Hepatology. 2012;56(3):1034–1043. doi:10.1002/hep.25740
   PubMed Web of Science ®Google Scholar
• Chiang JYL, Ferrell JM. Discovery of farnesoid X receptor and its role in bile acid metabolism. Mol Cell Endocrinol. 2022;548:111618. doi:10.1016/j.mce.2022.111618
   PubMed Web of Science ®Google Scholar
• Davis RA, Miyake JH, Hui TY, Spann NJ. Regulation of cholesterol-7alpha-hydroxylase: bAREly missing a SHP. J Lipid Res. 2002;43(4):533–543. doi:10.1016/S0022-2275(20)31482-6
   PubMed Web of Science ®Google Scholar
• Ma K, Saha PK, Chan L, Moore DD. Farnesoid X receptor is essential for normal glucose homeostasis. J Clin Invest. 2006;116(4):1102–1109. doi:10.1172/JCI25604
   PubMed Web of Science ®Google Scholar
• Zheng X, Chen T, Jiang R, et al. Hyocholic acid species improve glucose homeostasis through a distinct TGR5 and FXR signaling mechanism. Cell Metab. 2021;33(4):791–803.e7. doi:10.1016/j.cmet.2020.11.017
   PubMed Web of Science ®Google Scholar
• Kim D-H, Xiao Z, Kwon S, et al. A dysregulated acetyl/SUMO switch of FXR promotes hepatic inflammation in obesity. EMBO J. 2015;34(2):184–199. doi:10.15252/embj.201489527
   PubMed Web of Science ®Google Scholar
• Sinal CJ, Tohkin M, Miyata M, et al. Targeted disruption of the nuclear receptor FXR/BAR impairs bile acid and lipid homeostasis. Cell. 2000;102:731–744. doi:10.1016/s0092-8674(00)00062-3
   PubMed Web of Science ®Google Scholar
• Clifford BL, Sedgeman LR, Williams KJ, et al. FXR activation protects against NAFLD via bile-acid-dependent reductions in lipid absorption. Cell Metab. 2021;33(8):1671–1684.e4. doi:10.1016/j.cmet.2021.06.012
   PubMed Web of Science ®Google Scholar
• Seok S, Fu T, Choi S-E, et al. Transcriptional regulation of autophagy by an FXR/CREB axis. Nature. 2014;516(7529):108. doi:10.1038/nature13949
   PubMed Web of Science ®Google Scholar
• Lee JM, Wagner M, Xiao R, et al. Nutrient-sensing nuclear receptors coordinate autophagy. Nature. 2014;516(7529):112–115. doi:10.1038/nature13961
   PubMed Web of Science ®Google Scholar
• Han SY, Song HK, Cha JJ, et al. Farnesoid X receptor (FXR) agonist ameliorates systemic insulin resistance, dysregulation of lipid metabolism, and alterations of various organs in a type 2 diabetic kidney animal model. Acta Diabetol. 2021;58(4):495–503. doi:10.1007/s00592-020-01652-z
   PubMed Web of Science ®Google Scholar
• Owen BM, Milona A, van Mil S, et al. Intestinal Detoxification Limits the Activation of Hepatic Pregnane X Receptor by Lithocholic Acid. Drug Metab Dispos. 2010;38(1):143–149. doi:10.1124/dmd.109.029306
   PubMed Web of Science ®Google Scholar
• Fang S, Suh JM, Reilly SM, et al. Intestinal FXR agonism promotes adipose tissue browning and reduces obesity and insulin resistance. Nat Med. 2015;21(2):159–165. doi:10.1038/nm.3760
   PubMed Web of Science ®Google Scholar
• Pathak P, Xie C, Nichols RG, et al. Intestine farnesoid X receptor agonist and the gut microbiota activate G-protein bile acid receptor-1 signaling to improve metabolism. Hepatology. 2018;68(4):1574–1588. doi:10.1002/hep.29857
   PubMed Web of Science ®Google Scholar
• Dehondt H, Marino A, Butruille L, et al. Adipocyte-specific FXR-deficiency protects adipose tissue from oxidative stress and insulin resistance and improves glucose homeostasis. Mol Metab. 2023;69:101686. doi:10.1016/j.molmet.2023.101686
   PubMed Web of Science ®Google Scholar
• Yang J, de Vries HD, Mayeuf-Louchart A, et al. Role of bile acid receptor FXR in development and function of brown adipose tissue. Biochim Biophys Acta Mol Cell Biol Lipids. 2023;1868(2):159257. doi:10.1016/j.bbalip.2022.159257
   PubMed Web of Science ®Google Scholar
• Yty L, Swales KE, Thomas GJ, et al. Farnesoid X Receptor Ligands Inhibit Vascular Smooth Muscle Cell Inflammation and Migration. Arterioscler Thromb Vasc Biol. 2007;27(12):2606–2611. doi:10.1161/ATVBAHA.107.152694
   PubMed Web of Science ®Google Scholar
• Thomas C, Gioiello A, Noriega L, et al. TGR5-mediated bile acid sensing controls glucose homeostasis. Cell Metab. 2009;10(3):167–177. doi:10.1016/j.cmet.2009.08.001
   PubMed Web of Science ®Google Scholar
• Ding L, Yang Q, Zhang E, et al. Notoginsenoside Ft1 acts as a TGR5 agonist but FXR antagonist to alleviate high fat diet-induced obesity and insulin resistance in mice. Acta Pharm Sin B. 2021;11(6):1541–1554. doi:10.1016/j.apsb.2021.03.038
   PubMed Web of Science ®Google Scholar
• Watanabe M, Houten SM, Mataki C, et al. Bile acids induce energy expenditure by promoting intracellular thyroid hormone activation. Nature. 2006;439(7075):484–489. doi:10.1038/nature04330
   PubMed Web of Science ®Google Scholar
• Castellanos-Jankiewicz A, Guzmán-Quevedo O, Fénelon VS, et al. Hypothalamic bile acid-TGR5 signaling protects from obesity. Cell Metab. 2021;33(7):1483–1492.e10. doi:10.1016/j.cmet.2021.04.009
   PubMed Web of Science ®Google Scholar
• Sasaki T, Kuboyama A, Mita M, et al. The exercise-inducible bile acid receptor Tgr5 improves skeletal muscle function in mice. J Biol Chem. 2018;293(26):10322–10332. doi:10.1074/jbc.RA118.002733
   PubMed Web of Science ®Google Scholar
• Abrigo J, Gonzalez F, Aguirre F, et al. Cholic acid and deoxycholic acid induce skeletal muscle atrophy through a mechanism dependent on TGR5 receptor. J Cell Physiol. 2021;236(1):260–272. doi:10.1002/jcp.29839
   PubMed Web of Science ®Google Scholar
• Ichikawa R, Takayama T, Yoneno K, et al. Bile acids induce monocyte differentiation toward interleukin-12 hypo-producing dendritic cells via a TGR5-dependent pathway. Immunology. 2012;136(2):153–162. doi:10.1111/j.1365-2567.2012.03554.x
   PubMed Web of Science ®Google Scholar
• Biagioli M, Carino A, Cipriani S, et al. The Bile Acid Receptor GPBAR1 Regulates the M1/M2 Phenotype of Intestinal Macrophages and Activation of GPBAR1 Rescues Mice from Murine Colitis. J Immunol. 2017;199(2):718–733. doi:10.4049/jimmunol.1700183
   PubMed Web of Science ®Google Scholar
• Pols TWH, Nomura M, Harach T, et al. TGR5 activation inhibits atherosclerosis by reducing macrophage inflammation and lipid loading. Cell Metab. 2011;14(6):747–757. doi:10.1016/j.cmet.2011.11.006
   PubMed Web of Science ®Google Scholar
• Sorrentino G, Perino A, Yildiz E, et al. Bile Acids Signal via TGR5 to Activate Intestinal Stem Cells and Epithelial Regeneration. Gastroenterology. 2020;159(3):956–968.e8. doi:10.1053/j.gastro.2020.05.067
   PubMed Web of Science ®Google Scholar
• Ma X, Chen J, Tian Y. Pregnane X receptor as the “sensor and effector” in regulating epigenome. J Cell Physiol. 2015;230(4):752–757. doi:10.1002/jcp.24838
   PubMed Web of Science ®Google Scholar
• Han S, Li T, Ellis E, et al. A Novel Bile Acid-Activated Vitamin D Receptor Signaling in Human Hepatocytes. Mol Endocrinol. 2010;24(6):1151–1164. doi:10.1210/me.2009-0482
   PubMedGoogle Scholar
• Chaudhari SN, Luo JN, Harris DA, et al. A microbial metabolite remodels the gut-liver axis following bariatric surgery. Cell Host Microbe. 2021;29(3):408–424.e7. doi:10.1016/j.chom.2020.12.004
   PubMed Web of Science ®Google Scholar
• Pols TWH, Puchner T, Korkmaz HI, et al. Lithocholic acid controls adaptive immune responses by inhibition of Th1 activation through the Vitamin D receptor. PLoS One. 2017;12(5):e0176715. doi:10.1371/journal.pone.0176715
   PubMed Web of Science ®Google Scholar
• Yao B, He J, Yin X, et al. The protective effect of lithocholic acid on the intestinal epithelial barrier is mediated by the vitamin D receptor via a SIRT1/Nrf2 and NF-κB dependent mechanism in Caco-2 cells. Toxicol Lett. 2019;316:109–118. doi:10.1016/j.toxlet.2019.08.024
   PubMed Web of Science ®Google Scholar
• Durham AL, Speer MY, Scatena M, et al. Role of smooth muscle cells in vascular calcification: implications in atherosclerosis and arterial stiffness. Cardiovasc Res. 2018;114(4):590–600. doi:10.1093/cvr/cvy010
   PubMed Web of Science ®Google Scholar
• Sutton NR, Malhotra R, St. Hilaire C, et al. Molecular Mechanisms of Vascular Health: insights From Vascular Aging and Calcification. Arterioscler Thromb Vasc Biol. 2023;43(1):15–29. doi:10.1161/ATVBAHA.122.317332
   PubMed Web of Science ®Google Scholar
• Hashimoto N, Matsui I, Ishizuka S, et al. Lithocholic acid increases intestinal phosphate and calcium absorption in a vitamin D receptor dependent but transcellular pathway independent manner. Kidney Int. 2020;97(6):1164–1180. doi:10.1016/j.kint.2020.01.032
   PubMed Web of Science ®Google Scholar
• Miyazaki-Anzai S, Masuda M, Shiozaki Y, et al. Free Deoxycholic Acid Exacerbates Vascular Calcification in CKD through ER Stress-Mediated ATF4 Activation. Int J Med. 2021;360(2):857–868. DOI:10.34067/KID.0007502020
   Google Scholar
• Miyazaki-Anzai S, Levi M, Kratzer A, et al. Farnesoid X Receptor Activation Prevents the Development of Vascular Calcification in ApoE −/− Mice With Chronic Kidney Disease. Circ Res. 2010;106(12):1807–1817. doi:10.1161/CIRCRESAHA.109.212969
   PubMed Web of Science ®Google Scholar
• Pacifico L, Andreoli GM, D’Avanzo M, et al. Role of osteoprotegerin/receptor activator of nuclear factor kappa B/receptor activator of nuclear factor kappa B ligand axis in nonalcoholic fatty liver disease. World J Gastroenterol. 2018;24(19):2073–2082. doi:10.3748/wjg.v24.i19.2073
   PubMed Web of Science ®Google Scholar
• Allison MA, Criqui MH, Wright CM. Patterns and Risk Factors for Systemic Calcified Atherosclerosis. Arterioscler Thromb Vasc Biol. 2004;24(2):331–336. doi:10.1161/01.ATV.0000110786.02097.0c
   PubMed Web of Science ®Google Scholar
• New SEP, Aikawa E. Cardiovascular Calcification – an Inflammatory Disease –. Circulation Journal. 2011;75(6):1305–1313. doi:10.1253/circj.CJ-11-0395
   PubMed Web of Science ®Google Scholar
• Bessueille L, Magne D. Inflammation: a culprit for vascular calcification in atherosclerosis and diabetes. Cell Mol Life Sci. 2015;72(13):2475–2489. doi:10.1007/s00018-015-1876-4
   PubMed Web of Science ®Google Scholar
• Shioi A, Ikari Y. Plaque Calcification During Atherosclerosis Progression and Regression. J Atheroscler Thromb. 2018;25(4):294–303. doi:10.5551/jat.RV17020
   PubMed Web of Science ®Google Scholar
• Akers EJ, Nicholls SJ, Di Bartolo BA. Plaque Calcification. Arterioscler Thromb Vasc Biol. 2019;39(10):1902–1910. doi:10.1161/ATVBAHA.119.311574
   PubMed Web of Science ®Google Scholar
• Yahagi K, Kolodgie FD, Otsuka F, et al. Pathophysiology of native coronary, vein graft, and in-stent atherosclerosis. Nat Rev Cardiol. 2016;13(2):79–98. doi:10.1038/nrcardio.2015.164
   PubMed Web of Science ®Google Scholar
• Charach G, Grosskopf I, Rabinovich A, et al. The association of bile acid excretion and atherosclerotic coronary artery disease. Therap Adv Gastroenterol. 2011;4(2):95–101. doi:10.1177/1756283X10388682
   PubMedGoogle Scholar
• Liu S, He F, Zheng T, et al. Ligustrum robustum Alleviates Atherosclerosis by Decreasing Serum TMAO, Modulating Gut Microbiota, and Decreasing Bile Acid and Cholesterol Absorption in Mice. Mol Nutr Food Res. 2021;65(14):2100014. doi:10.1002/mnfr.202100014
   PubMed Web of Science ®Google Scholar
• Liu Y, Dou C, Wei G, et al. Usnea improves high-fat diet- and vitamin D3-induced atherosclerosis in rats by remodeling intestinal flora homeostasis. Front Pharmacol. 2022;13:1064872. doi:10.3389/fphar.2022.1064872
   PubMed Web of Science ®Google Scholar
• Ma Y, Li D, Liu W, et al. Resveratrol on the Metabolic Reprogramming in Liver: implications for Advanced Atherosclerosis. Front Pharmacol. 2021;12:747625. doi:10.3389/fphar.2021.747625
   PubMed Web of Science ®Google Scholar
• Byun S, Jung H, Chen J, et al. Phosphorylation of hepatic farnesoid X receptor by FGF19 signaling–activated Src maintains cholesterol levels and protects from atherosclerosis. J Biol Chem. 2019;294(22):8732–8744. doi:10.1074/jbc.RA119.008360
   PubMed Web of Science ®Google Scholar
• Fu Y, Feng H, Ding X, et al. Alisol B 23-acetate adjusts bile acid metabolisim via hepatic FXR-BSEP signaling activation to alleviate atherosclerosis. Phytomedicine. 2022;101:154120. doi:10.1016/j.phymed.2022.154120
   PubMed Web of Science ®Google Scholar
• Mencarelli A, Renga B, Distrutti E, Fiorucci S. Antiatherosclerotic effect of farnesoid X receptor. Am J Phys. 2009;296(2):H272–H281. doi:10.1152/ajpheart.01075.2008
   PubMed Web of Science ®Google Scholar
• Zhang Y, Wang X, Vales C, et al. FXR Deficiency Causes Reduced Atherosclerosis in Ldlr −/− Mice. Arterioscler Thromb Vasc Biol. 2006;26(10):2316–2321. doi:10.1161/01.ATV.0000235697.35431.05
   PubMed Web of Science ®Google Scholar
• Wu Q, Sun L, Hu X, et al. Suppressing the intestinal farnesoid X receptor/sphingomyelin phosphodiesterase 3 axis decreases atherosclerosis. J Clin Invest. 2021;131(9):e142865. doi:10.1172/JCI142865
   PubMed Web of Science ®Google Scholar
• Qi S, Luo X, Liu S, et al. The Critical Effect of Bile Acids in Atherosclerosis. J Cardiovasc Pharmacol. 2022;80(4):562. doi:10.1097/FJC.0000000000001320
   PubMed Web of Science ®Google Scholar
• Miyazaki-Anzai S, Masuda M, Levi M, et al. Dual Activation of the Bile Acid Nuclear Receptor FXR and G-Protein-Coupled Receptor TGR5 Protects Mice against Atherosclerosis. PLoS One. 2014;9(9):e108270. doi:10.1371/journal.pone.0108270
   PubMed Web of Science ®Google Scholar
• Miyazaki-Anzai S, Masuda M, Kohno S, et al. Simultaneous inhibition of FXR and TGR5 exacerbates atherosclerotic formation. J Lipid Res. 2018;59(9):1709–1713. doi:10.1194/jlr.M087239
   PubMed Web of Science ®Google Scholar
• Kida T, Tsubosaka Y, Hori M, et al. Bile Acid Receptor TGR5 Agonism Induces NO Production and Reduces Monocyte Adhesion in Vascular Endothelial Cells. Arterioscler Thromb Vasc Biol. 2013;33(7):1663–1669. doi:10.1161/ATVBAHA.113.301565
   PubMed Web of Science ®Google Scholar
• Schnatz PF, Nudy M, O’Sullivan DM, et al. Coronary Artery Vitamin D Receptor Expression and Plasma Concentrations of Vitamin D: their Association with Atherosclerosis. Menopause. 2012;19(9):967–973. doi:10.1097/gme.0b013e31824cfa8f
   PubMed Web of Science ®Google Scholar
• Oh J, Riek AE, Darwech I, et al. Deletion of Macrophage Vitamin D Receptor Promotes Insulin Resistance and Monocyte Cholesterol Transport to Accelerate Atherosclerosis in Mice. Cell Rep. 2015;10(11):1872–1886. doi:10.1016/j.celrep.2015.02.043
   PubMed Web of Science ®Google Scholar
• Sui Y, Meng Z, Park S-H, et al. Myeloid-specific deficiency of pregnane X receptor decreases atherosclerosis in LDL receptor-deficient mice[S]. J Lipid Res. 2020;61(5):696–706. doi:10.1194/jlr.RA119000122
   PubMed Web of Science ®Google Scholar
• Zhou C, King N, Chen KY, Breslow JL. Activation of PXR induces hypercholesterolemia in wild-type and accelerates atherosclerosis in apoE deficient mice. J Lipid Res. 2009;50(10):2004–2013. doi:10.1194/jlr.M800608-JLR200
   PubMed Web of Science ®Google Scholar
• Lin LM, Peng F, Liu YP, et al. Coadministration of VDR and RXR agonists synergistically alleviates atherosclerosis through inhibition of oxidative stress: an in vivo and in vitro study. Atherosclerosis. 2016;251:273–281. doi:10.1016/j.atherosclerosis.2016.06.005
   PubMed Web of Science ®Google Scholar
• Meissner M, Wolters H, de Boer RA, et al. Bile acid sequestration normalizes plasma cholesterol and reduces atherosclerosis in hypercholesterolemic mice. No additional effect of physical activity. Atherosclerosis. 2013;228(1):117–123. doi:10.1016/j.atherosclerosis.2013.02.021
   PubMed Web of Science ®Google Scholar
• Rattazzi M, Bertacco E, Puato M, et al. Hypertension and vascular calcification: a vicious cycle? J Hypertens. 2012;30(10):1885. doi:10.1097/HJH.0b013e328356c257
   PubMed Web of Science ®Google Scholar
• Kalra SS, Shanahan CM. Vascular calcification and hypertension: cause and effect. Ann Med. 2012;44(sup1):S85–S92. doi:10.3109/07853890.2012.660498
   PubMed Web of Science ®Google Scholar
• Ishimwe JA, Dola T, Ertuglu LA, Kirabo A. Bile acids and salt-sensitive hypertension: a role of the gut-liver axis. Am J Physiol Heart Circ Physiol. 2022;322(4):H636–H646. doi:10.1152/ajpheart.00027.2022
   PubMed Web of Science ®Google Scholar
• Li C, Li J, Weng X, et al. Farnesoid X receptor agonist CDCA reduces blood pressure and regulates vascular tone in spontaneously hypertensive rats. J Am Society oHypertension. 2015;9(7):507–516.e7. doi:10.1016/j.jash.2015.04.006
   PubMed Web of Science ®Google Scholar
• Guo C, Xie S, Chi Z, et al. Bile Acids Control Inflammation and Metabolic Disorder through Inhibition of NLRP3 Inflammasome. Immunity. 2016;45(4):802–816. doi:10.1016/j.immuni.2016.09.008
   PubMed Web of Science ®Google Scholar
• Zhang Q, He F, Kuruba R, et al. FXR-mediated regulation of angiotensin type 2 receptor expression in vascular smooth muscle cells. Cardiovasc Res. 2008;77(3):560–569. doi:10.1093/cvr/cvm068
   PubMed Web of Science ®Google Scholar
• Khurana S, Yamada M, Wess J, et al. Deoxycholyltaurine-induced vasodilation of rodent aorta is nitric oxide- and muscarinic M3 receptor-dependent. Eur J Pharmacol. 2005;517(1–2):103–110. doi:10.1016/j.ejphar.2005.05.037
   PubMed Web of Science ®Google Scholar
• Jadeja RN, Thounaojam MC, Bartoli M, Khurana S. Deoxycholylglycine, a conjugated secondary bile acid, reduces vascular tone by attenuating Ca2+ sensitivity via rho kinase pathway. Toxicol Appl Pharmacol. 2018;348:14–21. doi:10.1016/j.taap.2018.04.012
   PubMed Web of Science ®Google Scholar
• Pataia V, Papacleovoulou G, Nikolova V, et al. Paternal cholestasis exacerbates obesity-associated hypertension in male offspring but is prevented by paternal ursodeoxycholic acid treatment. Int J Obes. 2019;43(2):319–330. doi:10.1038/s41366-018-0095-0
   Web of Science ®Google Scholar
• Ren S-C, Mao N, Yi S, et al. Vascular Calcification in Chronic Kidney Disease: an Update and Perspective. Aging Dis. 2022;13(3):673–697. doi:10.14336/AD.2021.1024
   PubMed Web of Science ®Google Scholar
• Vervloet MG, van Ballegooijen AJ. Prevention and treatment of hyperphosphatemia in chronic kidney disease. Kidney Int. 2018;93(5):1060–1072. doi:10.1016/j.kint.2017.11.036
   PubMed Web of Science ®Google Scholar
• Zununi Vahed S, Mostafavi S, Hosseiniyan Khatibi SM, et al. Vascular Calcification: an Important Understanding in Nephrology. Vasc Health Risk Manag. 2020;16:167–180. doi:10.2147/VHRM.S242685
   PubMed Web of Science ®Google Scholar
• Villa-Bellosta R, Hamczyk MR, Andrés V. Novel phosphate-activated macrophages prevent ectopic calcification by increasing extracellular ATP and pyrophosphate. PLoS One. 2017;12(3):e0174998. doi:10.1371/journal.pone.0174998
   PubMed Web of Science ®Google Scholar
• Dai Z, Zhang X. Pathophysiology and Clinical Impacts of Chronic Kidney Disease on Coronary Artery Calcification. J Cardiovasc Dev Dis. 2023;10(5):207. doi:10.3390/jcdd10050207
   PubMed Web of Science ®Google Scholar
• Zhang Y-X, Tang R-N, Wang L-T, Liu B-C. Role of crosstalk between endothelial cells and smooth muscle cells in vascular calcification in chronic kidney disease. Cell Prolif. 2021;54(3):e12980. doi:10.1111/cpr.12980
   PubMed Web of Science ®Google Scholar
• Gai Z, Chu L, Hiller C, et al. Effect of chronic renal failure on the hepatic, intestinal, and renal expression of bile acid transporters. Am J Phys Renal Physiol. 2014;306(1):F130–F137. doi:10.1152/ajprenal.00114.2013
   PubMed Web of Science ®Google Scholar
• Wang X, Yang S, Li S, et al. Aberrant gut microbiota alters host metabolome and impacts renal failure in humans and rodents. Gut. 2020;69(12):2131–2142. doi:10.1136/gutjnl-2019-319766
   PubMed Web of Science ®Google Scholar
• Feng Y-L, Cao G, Chen D-Q, et al. Microbiome-metabolomics reveals gut microbiota associated with glycine-conjugated metabolites and polyamine metabolism in chronic kidney disease. Cellular and molecular life sciences. CMLS. 2019;76(24):4961–4978. doi:10.1007/s00018-019-03155-9
   PubMed Web of Science ®Google Scholar
• Zhang Z-M, Yang L, Wan Y, et al. Integrated gut microbiota and fecal metabolomics reveal the renoprotective effect of Rehmanniae Radix Preparata and Corni Fructus on adenine-induced CKD rats. J Chromatogr B Analyt Technol Biomed Life Sci. 2021;1174:122728. doi:10.1016/j.jchromb.2021.122728
   PubMed Web of Science ®Google Scholar
• Jovanovich A, Isakova T, Block G, et al. Deoxycholic Acid, a Metabolite of Circulating Bile Acids, and Coronary Artery Vascular Calcification in CKD. Am J Kidney Dis. 2018;71(1):27–34. doi:10.1053/j.ajkd.2017.06.017
   PubMed Web of Science ®Google Scholar
• Chen W, Fitzpatrick J, Sozio SM, et al. Identification of Novel Biomarkers and Pathways for Coronary Artery Calcification in Nondiabetic Patients on Hemodialysis Using Metabolomic Profiling. Kidney360. 2020;2:279–289. doi:10.34067/KID.0004422020
   Google Scholar
• Jovanovich A, Cai X, Frazier R, et al. Deoxycholic Acid and Coronary Artery Calcification in the Chronic Renal Insufficiency Cohort. J Am Heart Assoc. 2022;11(7):e022891. doi:10.1161/JAHA.121.022891
   PubMed Web of Science ®Google Scholar
• Masuda M, Miyazaki‐Anzai S, Levi M, et al. PERK‐eIF2α‐ATF4‐CHOP Signaling Contributes to TNFα‐Induced Vascular Calcification. J Am Heart Assoc. 2013;2(5):e000238. doi:10.1161/JAHA.113.000238
   PubMed Web of Science ®Google Scholar
• Li C, Zhang S, Chen X, et al. Farnesoid X receptor activation inhibits TGFBR1/TAK1-mediated vascular inflammation and calcification via miR-135a-5p. Commun Biol. 2020;3(1):327. doi:10.1038/s42003-020-1058-2
   PubMed Web of Science ®Google Scholar
• Zhao K, He J, Zhang Y, et al. Activation of FXR protects against renal fibrosis via suppressing Smad3 expression. Sci Rep. 2016;6(1):37234. doi:10.1038/srep37234
   PubMedGoogle Scholar
• Hu Z, Ren L, Wang C, et al. Effect of Chenodeoxycholic Acid on Fibrosis, Inflammation and Oxidative Stress in Kidney in High-Fructose-Fed Wistar Rats. Kidney Blood Press Res. 2012;36(2):85–97. doi:10.1159/000341485
   PubMedGoogle Scholar
• Wang XX, Jiang T, Shen Y, et al. The farnesoid X receptor modulates renal lipid metabolism and diet-induced renal inflammation, fibrosis, and proteinuria. Am J Physiol Renal Physiol. 2009;297(6):F1587–1596. doi:10.1152/ajprenal.00404.2009
   PubMed Web of Science ®Google Scholar
• Wang XX, Wang D, Luo Y, et al. FXR/TGR5 Dual Agonist Prevents Progression of Nephropathy in Diabetes and Obesity. J Am Soc Nephrol. 2018;29(1):118–137. doi:10.1681/ASN.2017020222
   PubMed Web of Science ®Google Scholar
• Panda DK, Bai X, Sabbagh Y, et al. Defective interplay between mTORC1 activity and endoplasmic reticulum stress-unfolded protein response in uremic vascular calcification. Am J Phys Renal Physiol. 2018;314(6):F1046–F1061. doi:10.1152/ajprenal.00350.2017
   PubMed Web of Science ®Google Scholar
• Yoon YM, Kim S, Han Y-S, et al. TUDCA-treated chronic kidney disease-derived hMSCs improve therapeutic efficacy in ischemic disease via PrPC. Redox Biol. 2019;22:101144. doi:10.1016/j.redox.2019.101144
   PubMed Web of Science ®Google Scholar
• Li L, Guo Z-Y, Wang J, et al. Tauroursodeoxycholic acid inhibits TGF-β1-induced renal fibrosis markers in cultured renal mesangial cells by regulating endoplasmic reticulum stress. Exp Ther Med. 2022;23(6):432. doi:10.3892/etm.2022.11359
   PubMed Web of Science ®Google Scholar
• Yun SP, Yoon YM, Lee JH, et al. Tauroursodeoxycholic Acid Protects against the Effects of P-Cresol-Induced Reactive Oxygen Species via the Expression of Cellular Prion Protein. Int J Mol Sci. 2018;19(2):352. doi:10.3390/ijms19020352
   PubMed Web of Science ®Google Scholar
• Hartmann P, Hochrath K, Horvath A, et al. Modulation of the intestinal bile acid/farnesoid X receptor/fibroblast growth factor 15 axis improves alcoholic liver disease in mice. Hepatology. 2018;67(6):2150–2166. doi:10.1002/hep.29676
   PubMed Web of Science ®Google Scholar
• Zheng T, Kim N-Y, Yim M. Fexaramine Inhibits Receptor Activator of Nuclear Factor-κB Ligand-induced Osteoclast Formation via Nuclear Factor of Activated T Cells Signaling Pathways. J Bone Metab. 2017;24(4):207–215. doi:10.11005/jbm.2017.24.4.207
   PubMedGoogle Scholar
• Jiang T, Wang XX, Scherzer P, et al. Farnesoid X receptor modulates renal lipid metabolism, fibrosis, and diabetic nephropathy. Diabetes. 2007;56(10):2485–2493. doi:10.2337/db06-1642
   PubMed Web of Science ®Google Scholar
• Li L, Zhao H, Chen B, et al. FXR activation alleviates tacrolimus-induced post-transplant diabetes mellitus by regulating renal gluconeogenesis and glucose uptake. J Transl Med. 2019;17(1):418. doi:10.1186/s12967-019-02170-5
   PubMed Web of Science ®Google Scholar
• Kim D-H, Park JS, Choi H-I, et al. The critical role of FXR is associated with the regulation of autophagy and apoptosis in the progression of AKI to CKD. Cell Death Dis. 2021;12(4):320. doi:10.1038/s41419-021-03620-z
   PubMed Web of Science ®Google Scholar
• Hu T, Chouinard M, Cox AL, et al. Farnesoid X Receptor Agonist Reduces Serum Asymmetric Dimethylarginine Levels through Hepatic Dimethylarginine Dimethylaminohydrolase-1 Gene Regulation*. J Biol Chem. 2006;281(52):39831–39838. doi:10.1074/jbc.M606779200
   PubMed Web of Science ®Google Scholar
• Fujimori K, Iguchi Y, Yamashita Y, et al. Synthesis of Novel Farnesoid X Receptor Agonists and Validation of Their Efficacy in Activating Differentiation of Mouse Bone Marrow-Derived Mesenchymal Stem Cells into Osteoblasts. Molecules. 2019;24(22):4155. doi:10.3390/molecules24224155
   PubMed Web of Science ®Google Scholar
• Wang XX, Jiang T, Shen Y, et al. Diabetic nephropathy is accelerated by farnesoid X receptor deficiency and inhibited by farnesoid X receptor activation in a type 1 diabetes model. Diabetes. 2010;59(11):2916–2927. doi:10.2337/db10-0019
   PubMed Web of Science ®Google Scholar
• Lin C, Yu B, Liu X, et al. Obeticholic acid inhibits hepatic fatty acid uptake independent of FXR in mouse. Biomed Pharmacother. 2022;150:112984. doi:10.1016/j.biopha.2022.112984
   PubMed Web of Science ®Google Scholar
• Kumar DP, Rajagopal S, Mahavadi S, et al. Activation of transmembrane bile acid receptor TGR5 stimulates insulin secretion in pancreatic β cells. Biochem Biophys Res Commun. 2012;427(3):600–605. doi:10.1016/j.bbrc.2012.09.104
   PubMed Web of Science ®Google Scholar
• Kumar DP, Asgharpour A, Mirshahi F, et al. Activation of Transmembrane Bile Acid Receptor TGR5 Modulates Pancreatic Islet α Cells to Promote Glucose Homeostasis. J Biol Chem. 2016;291(13):6626–6640. doi:10.1074/jbc.M115.699504
   PubMed Web of Science ®Google Scholar
• Wang XX, Edelstein MH, Gafter U, et al. G Protein-Coupled Bile Acid Receptor TGR5 Activation Inhibits Kidney Disease in Obesity and Diabetes. J Am Soc Nephrology. 2016;27(5):1362. doi:10.1681/ASN.2014121271
   PubMed Web of Science ®Google Scholar
• Rizzo G, Passeri D, De Franco F, et al. Functional Characterization of the Semisynthetic Bile Acid Derivative INT-767, a Dual Farnesoid X Receptor and TGR5 Agonist. Mol Pharmacol. 2010;78(4):617–630. doi:10.1124/mol.110.064501
   PubMed Web of Science ®Google Scholar
• Comeglio P, Cellai I, Mello T, et al. INT-767 prevents NASH and promotes visceral fat brown adipogenesis and mitochondrial function. J Endocrinol. 2018;238(2):107–127. doi:10.1530/JOE-17-0557
   PubMed Web of Science ®Google Scholar
• McMahan RH, Wang XX, Cheng LL, et al. Bile acid receptor activation modulates hepatic monocyte activity and improves nonalcoholic fatty liver disease. J Biol Chem. 2013;288(17):11761–11770. doi:10.1074/jbc.M112.446575
   PubMed Web of Science ®Google Scholar
• Jadhav K, Xu Y, Xu Y, et al. Reversal of metabolic disorders by pharmacological activation of bile acid receptors TGR5 and FXR. Mol Metab. 2018;9:131–140. doi:10.1016/j.molmet.2018.01.005
   PubMed Web of Science ®Google Scholar
• Lanzer P, Hannan FM, Lanzer JD, et al. Medial Arterial Calcification: JACC State-of-The-Art Review. J Am Coll Cardiol. 2021;78(11):1145–1165. doi:10.1016/j.jacc.2021.06.049
   PubMed Web of Science ®Google Scholar
• Yahagi K, Kolodgie FD, Lutter C, et al. ATVB in Focus series on Vascular Calcification in Diabetes. Arterioscler Thromb Vasc Biol. 2017;37(2):191–204. doi:10.1161/ATVBAHA.116.306256
   PubMed Web of Science ®Google Scholar
• Boström KI, Jumabay M, Matveyenko A, et al. Activation of Vascular Bone Morphogenetic Protein Signaling in Diabetes Mellitus. Circ Res. 2011;108(4):446–457. doi:10.1161/CIRCRESAHA.110.236596
   PubMed Web of Science ®Google Scholar
• Fadini GP, Albiero M, Menegazzo L, et al. Widespread Increase in Myeloid Calcifying Cells Contributes to Ectopic Vascular Calcification in Type 2 Diabetes. Circ Res. 2011;108(9):1112–1121. doi:10.1161/CIRCRESAHA.110.234088
   PubMed Web of Science ®Google Scholar
• Yuan X, Wang R, Han B, et al. Functional and metabolic alterations of gut microbiota in children with new-onset type 1 diabetes. Nat Commun. 2022;13(1):6356. doi:10.1038/s41467-022-33656-4
   PubMed Web of Science ®Google Scholar
• Lamichhane S, Sen P, Dickens AM, et al. Dysregulation of secondary bile acid metabolism precedes islet autoimmunity and type 1 diabetes. Cell Rep Med. 2022;3(10):100762. doi:10.1016/j.xcrm.2022.100762
   PubMedGoogle Scholar
• Zhao L, Lou H, Peng Y, et al. Elevated levels of circulating short-chain fatty acids and bile acids in type 2 diabetes are linked to gut barrier disruption and disordered gut microbiota. Diabetes Res Clin Pract. 2020;169:108418. doi:10.1016/j.diabres.2020.108418
   PubMed Web of Science ®Google Scholar
• Sonne DP, van Nierop FS, Kulik W, et al. Postprandial Plasma Concentrations of Individual Bile Acids and FGF-19 in Patients With Type 2 Diabetes. J Clin Endocrinol Metab. 2016;101(8):3002–3009. doi:10.1210/jc.2016-1607
   PubMed Web of Science ®Google Scholar
• Wang X-H, Xu F, Cheng M, et al. Fasting serum total bile acid levels are associated with insulin sensitivity, islet β-cell function and glucagon levels in response to glucose challenge in patients with type 2 diabetes. Endocr J. 2020;67(11):1107–1117. doi:10.1507/endocrj.EJ20-0201
   PubMed Web of Science ®Google Scholar
• Sonne DP, Hansen M, Knop FK. MECHANISMS IN ENDOCRINOLOGY: bile acid sequestrants in type 2 diabetes: potential effects on GLP1 secretion. Eur J Endocrinol. 2014;171(2):R47–R65. doi:10.1530/EJE-14-0154
   PubMed Web of Science ®Google Scholar
• Gao J, Xu B, Zhang X, et al. Association between serum bile acid profiles and gestational diabetes mellitus: a targeted metabolomics study. Clinica Chimica Acta. 2016;459:63–72. doi:10.1016/j.cca.2016.05.026
   PubMed Web of Science ®Google Scholar
• Chaudhari SN, Harris DA, Aliakbarian H, et al. Bariatric surgery reveals a gut-restricted TGR5 agonist with anti-diabetic effects. Nat Chem Biol. 2021;17(1):20–29. doi:10.1038/s41589-020-0604-z
   PubMed Web of Science ®Google Scholar
• Roschger P, Misof B, Paschalis E, et al. Changes in the Degree of Mineralization with Osteoporosis and its Treatment. Curr Osteoporos Rep. 2014;12(3):338–350. doi:10.1007/s11914-014-0218-z
   PubMed Web of Science ®Google Scholar
• Lampropoulos CE, Kalamara P, Konsta M, et al. Osteoporosis and vascular calcification in postmenopausal women: a cross-sectional study. Climacteric. 2016;19(3):303–307. doi:10.3109/13697137.2016.1164134
   PubMed Web of Science ®Google Scholar
• Hou Y-C, Lu C-L, Lu K-C. Mineral bone disorders in chronic kidney disease. Nephrology. 2018;23(S4):88–94. doi:10.1111/nep.13457
   PubMedGoogle Scholar
• Demer LL, Tintut Y. Inflammatory, metabolic, and genetic mechanisms of vascular calcification. Arterioscler Thromb Vasc Biol. 2014;34(4):715–723. doi:10.1161/ATVBAHA.113.302070
   PubMed Web of Science ®Google Scholar
• Reid IR, Bristow SM. Calcium and Bone. In: Stern PH, editor. Bone Regulators and Osteoporosis Therapy. Springer International Publishing, Cham; 2020:259–280.
   Google Scholar
• Bihari C, Lal D, Thakur M, et al. Suboptimal Level of Bone‐Forming Cells in Advanced Cirrhosis are Associated with Hepatic Osteodystrophy. Hepatol Commun. 2018;2(9):1095–1110. doi:10.1002/hep4.1234
   PubMed Web of Science ®Google Scholar
• Guañabens N, Ruiz-Gaspà S, Gifre L, et al. Sclerostin Expression in Bile Ducts of Patients With Chronic Cholestasis May Influence the Bone Disease in Primary Biliary Cirrhosis. J Bone Minera Res. 2016;31(9):1725–1733. doi:10.1002/jbmr.2845
   PubMed Web of Science ®Google Scholar
• Fonseca V, Epstein O, Gill DS, et al. Hyperparathyroidism and Low Serum Osteocalcin Despite Vitamin D Replacement in Primary Biliary Cirrhosis. J Clin Endocrinol Metab. 1987;64(5):873–877. doi:10.1210/jcem-64-5-873
   PubMed Web of Science ®Google Scholar
• Zhao Y-X, Song Y-W, Zhang L, et al. Association between bile acid metabolism and bone mineral density in postmenopausal women. Clinics. 2020;75:e1486. doi:10.6061/clinics/2020/e1486
   PubMed Web of Science ®Google Scholar
• Bellissimo MP, Roberts JL, Jones DP, et al. Metabolomic Associations with Serum Bone Turnover Markers. Nutrients. 2020;12(10):3161. doi:10.3390/nu12103161
   PubMed Web of Science ®Google Scholar
• Wen K, Tao L, Tao Z, et al. Fecal and Serum Metabolomic Signatures and Microbial Community Profiling of Postmenopausal Osteoporosis Mice Model. Front Cell Infect Microbiol. 2020;10:535310. doi:10.3389/fcimb.2020.535310
   PubMed Web of Science ®Google Scholar
• Deng D, Pan C, Wu Z, et al. An Integrated Metabolomic Study of Osteoporosis: discovery and Quantification of Hyocholic Acids as Candidate Markers. Front Pharmacol. 2021;12:725341. doi:10.3389/fphar.2021.725341
   PubMed Web of Science ®Google Scholar
• Cho SW, An JH, Park H, et al. Positive regulation of osteogenesis by bile acid through FXR. J Bone Minera Res. 2013;28(10):2109–2121. doi:10.1002/jbmr.1961
   PubMed Web of Science ®Google Scholar
• Id Boufker H, Lagneaux L, Fayyad-Kazan H, et al. Role of farnesoid X receptor (FXR) in the process of differentiation of bone marrow stromal cells into osteoblasts. Bone. 2011;49(6):1219–1231. doi:10.1016/j.bone.2011.08.013
   PubMed Web of Science ®Google Scholar
• Li Z, Huang J, Wang F, et al. Dual Targeting of Bile Acid Receptor-1 (TGR5) and Farnesoid X Receptor (FXR) Prevents Estrogen-Dependent Bone Loss in Mice. J Bone Minera Res. 2019;34(4):765–776. doi:10.1002/jbmr.3652
   PubMed Web of Science ®Google Scholar
• Wang Q, Wang G, Wang B, Yang H. Activation of TGR5 promotes osteoblastic cell differentiation and mineralization. Biomed Pharm. 2018;108:1797–1803. doi:10.1016/j.biopha.2018.08.093
   PubMed Web of Science ®Google Scholar
• Ruiz-Gaspà S, Guañabens N, Enjuanes A, et al. Lithocholic acid downregulates vitamin D effects in human osteoblasts. Eur J Clin Invest. 2010;40(1):25–34. doi:10.1111/j.1365-2362.2009.02230.x
   PubMed Web of Science ®Google Scholar
• Ruiz-Gaspà S, Guañabens N, Jurado S, et al. Bilirubin and bile acids in osteocytes and bone tissue. Potential role in the cholestatic-induced osteoporosis. Liver Int. 2020;40(11):2767–2775. doi:10.1111/liv.14630
   PubMed Web of Science ®Google Scholar
• Ruiz-Gaspà S, Guañabens N, Jurado S, et al. Bile acids and bilirubin effects on osteoblastic gene profile. Implications in the pathogenesis of osteoporosis in liver diseases. Gene. 2020;725:144167. doi:10.1016/j.gene.2019.144167
   PubMed Web of Science ®Google Scholar
• Ahn T-K, Kim K-T, Joshi HP, et al. Therapeutic Potential of Tauroursodeoxycholic Acid for the Treatment of Osteoporosis. Int J Mol Sci. 2020;21(12):4274. doi:10.3390/ijms21124274
   PubMed Web of Science ®Google Scholar
• Chandran M, Tay D, Mithal A. Supplemental calcium intake in the aging individual: implications on skeletal and cardiovascular health. Aging Clin Exp Res. 2019;31(6):765–781. doi:10.1007/s40520-019-01150-5
   PubMed Web of Science ®Google Scholar